Esperion Therapeutics (ESPR) Earning Somewhat Positive Press Coverage, Analysis Shows
Media headlines about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.5158810112032 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Reviewing Esperion Therapeutics (ESPR) & Its Competitors (americanbankingnews.com)
- Brokerages Expect Esperion Therapeutics, Inc. (ESPR) to Post -$1.78 Earnings Per Share (americanbankingnews.com)
- Head-To-Head Survey: Esperion Therapeutics (ESPR) vs. Its Competitors (americanbankingnews.com)
- Esperion Therapeutics : Stocks Under Scanner in the Biotech Space — Curis, Egalet, and Esperion Therapeutics (4-traders.com)
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 2.49% on Friday, reaching $51.93. The company’s stock had a trading volume of 1,224,283 shares. Esperion Therapeutics has a one year low of $9.40 and a one year high of $57.38. The firm’s market capitalization is $1.17 billion. The firm has a 50-day moving average price of $48.12 and a 200 day moving average price of $40.42.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.25). During the same period in the prior year, the company earned ($0.62) earnings per share. On average, analysts anticipate that Esperion Therapeutics will post ($7.29) earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on ESPR shares. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price objective (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Deutsche Bank AG set a $64.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group LLC upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and dropped their price target for the company from $85.00 to $55.00 in a research report on Tuesday, August 8th. UBS AG restated a “buy” rating and set a $57.00 price target (up from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Finally, BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, June 25th. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $52.54.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.